Company Overview of Emmaus Life Sciences, Inc.
Emmaus Life Sciences, Inc. is engaged in the discovery, development, and commercialization of treatments and therapies for rare and orphan diseases. The company’s lead product candidate includes pharmaceutical-grade L-glutamine, which has completed Phase III clinical trials for the treatment of sickle cell disease. It also markets and sells NutreStore, an L-glutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support; and sells L-glutamine as a nutritional supplement under the AminoPure brand name through retail stores in various states, as well as through importers and distributors in Japan, Taiwan, and South Korea. The com...
20725 South Western Avenue
Torrance, CA 90501
Founded in 2000
Key Executives for Emmaus Life Sciences, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Executive Vice President
Senior Vice President of Finance
Senior Vice President of Research and Development
Compensation as of Fiscal Year 2014.
Emmaus Life Sciences, Inc. Key Developments
Emmaus Life Sciences, Inc. Announces Results of Phase 3 Clinical Trial of Patented Oral Pharmaceutical Grade L-Glutamine Treatment for Sickle Cell Anemia and Sickle
Feb 2 15
Emmaus Life Sciences, Inc. announced that the results of the Company's Phase 3 clinical trial of its patented oral pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia was included in the American Society of Hematology's official 2015 Highlights of ASH. These Phase 3 results were initially presented in December 2014 at the ASH Annual Meeting. The Phase 3 multi-center, double blind clinical trial studied the efficacy and safety of PGLG for sickle cell disease (SCD) in 230 pediatric patients as young as five years old and adults. Study participants were randomized to receive daily PGLG (152 patients) or placebo (78 patients) for 48 weeks, after which treatment levels were tapered to zero. Researchers observed that patients who received PGLG experienced fewer painful crises (3 vs. 4 events during the study period, a 25% reduction) and a longer time to a pain crisis than patients receiving placebo. Treated patients were also less likely to be hospitalized for their condition (2 vs. 3 events during the study period, a 33% reduction) and spent less time in the hospital for these events (6.5 vs. 11 days, a 41% reduction) than those receiving placebo. The percentage of patients experiencing acute chest syndrome, a severe complication of SCD, was less than half among the PGLG group as compared to the placebo group (11.9% vs. 26.9%, or 58% fewer cases). The treatment was well tolerated, as safety profiles were similar
among the PGLG and placebo groups.
Emmaus Life Sciences, Inc. Announces Resignation of Duane Kurisu to the Board of Directors
Jan 15 15
On January 9, 2015, Emmaus Life Sciences, Inc. received notice from Mr. Duane Kurisu of his resignation from the Board of Directors of the company. Mr. Kurisu's resignation was not due to any disagreement with the Company and, in accordance with the Company's By-laws, was effective on January 9, 2015.
Emmaus Life Sciences, Inc., Annual General Meeting, Oct 23, 2014
Sep 19 14
Emmaus Life Sciences, Inc., Annual General Meeting, Oct 23, 2014., at 09:00 Pacific Standard Time. Location: DoubleTree Hotel located at 21333 Hawthorne Blvd.. Agenda: To elect the directors named in the accompanying Proxy Statement to hold office until the 2015 Annual Meeting of Stockholders; to ratify the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2014; to conduct a non-binding advisory vote on its 2013 executive compensation; to ratify a recent amendment to 2011 Stock Incentive Plan; and to transact such other business as may properly come before the Annual Meeting and any adjournment or postponement thereof.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 12, 2014